Menu
Menu
The biomanufacturing industry would benefit from rapid, scalable, and informative analytical measurements for use during biologics production that would speed up the development and production of vaccines and therapeutics.
The University of Maryland, College Park, aimed to develop a microfluidic analytic device for the rapid quantification of antibody titer and N-linked galactosylation. The device is integrated with bioelectronic sensor technology that can quickly inform the total proportion of galactosylated antibodies in a sample. If successful, this device would reduce cost and time associated with the development and production processes of biologics by generating rapid analysis of vital analytical features of antibody therapeutics.
The University of Maryland developed a novel platform for rapid analysis of vital analytical features of antibody therapeutics such as antibody titer and glycan structure. This integrated device and sensor technology will help improve the process development and production efficiency of critically important vaccines and therapeutics for the coronavirus response effort.
The University of Maryland developed a novel platform for rapid analysis of vital analytical features of antibody therapeutics such as antibody titer and glycan structure. This integrated device and sensor technology will help improve the process development and production efficiency of critically important vaccines and therapeutics for the coronavirus response effort.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
University of Maryland College Park